BDTX241220P2500
- 0.15
- -0.05-25.00%
Black Diamond Therapeutics Newsroom
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Cuts Target Price to $16
Express News | Black Diamond Therapeutics Inc : Stifel Cuts Target Price to $16 From $18
Black Diamond Therapeutic Analyst Ratings
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating
Strong Buy Rating for Black Diamond Therapeutics Driven by Financial Stability and Promising Clinical Developments
Express News | Black Diamond Therapeutics Inc: Clinical Updates of Bdtx-1535 in Egfrm Nsclc and Regulatory Feedback Expected in Q1 2025
Black Diamond Theraptcs 3Q Loss/Shr 28c >BDTX
Express News | Black Diamond Therapeutics Q3 Income From Operations USD -18.13 Million
Express News | Black Diamond Therapeutics Q3 Operating Expenses USD 18.13 Million
Express News | Black Diamond Therapeutic's Cash, Cash Equivalents, And Investments Of $112.7M As Of September 30, 2024; Expected To Be Sufficient To Fund Operations Into Q2 Of 2026
Express News | Black Diamond Therapeutic Q3 2024 GAAP EPS $(0.28) Beats $(0.38) Estimate
Black Diamond Therapeutics | 10-Q: Q3 2024 Earnings Report
Black Diamond Therapeutics | 8-K: Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $11
A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $11 to $16
Express News | HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target
Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), MiNK Therapeutics (INKT)
Black Diamond Therapeutic Analyst Ratings